{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.4","upperLimit":"50.2","value":"41.1"},{"groupId":"OG001","lowerLimit":"22.3","upperLimit":"42.5","value":"26.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.8","upperLimit":"36.3","value":"30.7"},{"groupId":"OG001","lowerLimit":"23.9","upperLimit":"30.3","value":"26.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"162"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"44.0","value":"30.2"},{"comment":"The median survival time was not reached because too few deaths occurred in this subgroup to allow estimation of the median and its associated upper confidence bound.","groupId":"OG001","lowerLimit":"78.1","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"NIH-required analysis. Overall survival (OS) is estimated by the Kaplan-Meier method. Survival time is measured from step 2 randomization to date of death from any cause or last known follow-up (censored). Analysis was to occur at the earlier of 316 reported deaths or when all patients have five years potential follow-up from step 2 randomization.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive the same treatment as in arm I or arm II for one month. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.","id":"OG000","title":"Arm III (Chemotherapy)"},{"description":"Patients receive the same treatment as in arm I or arm II for one month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (RT) (3-dimensional conformal radiotherapy or intensity modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed. Patients undergo CT, MRI, and/or x-ray imaging throughout the trial. Patients also undergo blood sample collection during screening and follow-up and undergo tissue sample collection at baseline.","id":"OG001","title":"Arm IV (Chemotherapy, Chemoradiotherapy)"}],"paramType":"MEDIAN","populationDescription":"Participants randomized at step 2. Data were stratified by ethnicity.","reportingStatus":"POSTED","timeFrame":"From step 2 randomization (chemotherapy vs. chemotherapy followed by chemoradiation) to the date of death or last follow-up. Maximum follow-up at time of the phase III analysis was 12.8 years, measured from step 2 randomization.","title":"Overall Survival (Percentage of Participants Alive) [Phase III] by Ethnicity","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}